Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by wofatson Apr 11, 2022 10:52pm
153 Views
Post# 34595784

A nibble

A nibble

MONTREAL, April 11, 2022 /CNW/ - Long Zone Holdings Inc. ("the Corporation") announced that on March 22, 2022 Jonathan Ross Goodman, the president, shareholder and sole director of the Corporation, acquired 1,149 common shares under the employee stock purchase plan of Knight Therapeutics Inc. ("Knight") ("the Acquired Shares"), at a price of $5.46 per common share for an aggregate consideration of $6,273.54. The Acquired Shares, together with common shares of Knight acquired since June 2, 2016, represent approximately 0.53% of the outstanding common shares of Knight (the "Knight Shares").

Prior to the acquisition of the Acquired Shares, Jonathan Ross Goodman, together with the Corporation, directly and indirectly held 22,445,143 Knight Shares representing approximately 19.2% of the then outstanding Knight Shares. Immediately after the acquisition of the Acquired Shares, Jonathan Ross Goodman, together with the Corporation, directly and indirectly owns 22,446,292 Knight Shares representing approximately 19.2% of the outstanding Knight Shares as at March 22, 2022, and representing approximately 19.3% of the outstanding Knight Shares as at March 31, 2022 due to repurchases pursuant to Knight's normal course issuer bid.

 
<< Previous
Bullboard Posts
Next >>